A concise overview of a prospective controlled cohort study assessing whether adding low-dose colchicine (0.5 mg daily) to stable vitamin K antagonist (VKA) therapy in adults with chronic coronary disease affects anticoagulation control. Primary outcome: INR changes; secondary outcomes: VKA dose adjustments and time in therapeutic range (TTR). Findings: initiation, continuation, or withdrawal of low-dose colchicine did not significantly alter INR, VKA dosing, or TTR, supporting safe coadministration without additional INR monitoring beyond standard care. Limitations include short follow-up, exclusion of unstable disease and severe renal/hepatic impairment, and lack of formal safety assessment for bleeding or thrombosis. Clinical implications: aligns with existing guidelines and suggests simpler anticoagulation management when colchicine is added in stable patients, though vigilance during early use and consideration of polypharmacy remain important. Future research: longer-term studies and evaluation in special populations, including those with renal impairment or on multiple interacting drugs.